Tempus AI Stock Jumps 11% After Strong Q3 Earnings Beat Drives Analyst Upgrades

Tempus AI Delivers Strong Q3 Results

Tempus AI1

1

posted impressive Q3 earnings that exceeded Wall Street expectations, with the NASDAQ:TEM stock surging 11% following the announcement2

2

. The AI healthcare company reported adjusted earnings of $0.07 per share, a significant swing from the prior-year loss of $0.08 per share and well above the consensus estimate of a $0.11 per-share loss. Revenue jumped 23% year-over-year to $411.54 million, narrowly beating analyst expectations of $409.35 million.

Oncology Diagnostics Growth Accelerates

The company's oncology diagnostics business demonstrated remarkable momentum with unit volumes increasing 32% during the quarter. Particularly notable was the quadrupling of minimal residual disease detection tests to approximately 12,000, signaling strong adoption of Tempus AI's diagnostic platform. Eric Lefkofsky, founder and CEO of Tempus, emphasized that Q3 represented another record quarter, highlighting how the company's best-in-class diagnostic platform enhances its data and AI offerings while distinguishing the business from competitors.

Data & Applications Revenue Shows Momentum

The Data & Applications segment posted strong Q3 results with 33% revenue growth to $108.1 million, driven by increasing demand from pharmaceutical companies for medical data and AI models. Major pharmaceutical partners including AstraZeneca, Bristol Myers Squibb, and Merck are leveraging Tempus AI's extensive genetic and clinical databases to identify patients likely to respond to treatments, discover new biomarkers, and optimize clinical trials. Since January, new data licensing orders have exceeded $550 million, demonstrating the growing value pharmaceutical companies place on AI-driven precision medicine capabilities.

Profitability Path Takes Shape

Adjusted EBITDA reached $25.6 million in Q3, a substantial improvement from just $1.5 million in the prior-year quarter, indicating meaningful progress toward profitability. This performance validates the durability of Tempus AI's business model and its ability to translate revenue growth into improving margins. The company is also developing customized AI models for pharmaceutical partners, a development that could strengthen revenue visibility through multiyear contracts and enhance its role in pharmaceutical research.

Analyst Price Targets Rise Following Earnings

Multiple analysts raised their price targets on Tempus AI stock following the strong Q3 results. BTIG analyst Mark Massaro maintained a Buy rating and increased the price target from $80 to $100. Jefferies analyst Tycho Peterson upgraded the stock from Underperform to Hold while raising the target from $35 to $70. Cantor Fitzgerald analyst Sarah James maintained an Overweight rating and lifted the target from $80 to $92, while Baird analyst Catherine Schulte kept an Outperform rating and boosted the target from $85 to $92.

Mixed Signals and Future Outlook

Despite the strong Q3 performance, some challenges remain visible. Growth in hereditary diagnostics slowed to just 3%, and the company continues to report losses under GAAP accounting standards. Tempus AI slightly raised its full-year revenue forecast to between $1.60 billion and $1.605 billion but maintained its adjusted EBITDA target of $65 million. The planned $1.5 billion acquisition of Personalis could accelerate development in minimal residual disease detection, though it will require additional funding. Watch for how Tempus AI balances growth investments with its path to profitability, and whether pharmaceutical partnerships continue expanding as AI healthcare adoption accelerates across the industry.